{
    "ticker": "IMMP",
    "name": "Immutep Limited",
    "description": "Immutep Limited is a biotechnology company focused on developing innovative immunotherapy treatments for cancer and autoimmune diseases. Founded in 2001 and headquartered in Sydney, Australia, Immutep is a leader in the field of LAG-3 (Lymphocyte Activation Gene 3) research and drug development. The company is dedicated to improving patient outcomes by harnessing the power of the immune system through its proprietary LAG-3-related technologies. Immutep's lead product candidate, eftilagimod alpha (IMP321), is currently in clinical trials for various cancer indications, including metastatic breast cancer and head and neck squamous cell carcinoma. Additionally, Immutep has several ongoing collaborations with prominent pharmaceutical companies that aim to enhance the efficacy of cancer treatments by combining their LAG-3 technology with other immunotherapies. The company is committed to advancing its pipeline and expanding its therapeutic applications to address unmet medical needs in oncology and autoimmune diseases. With a strong focus on research and development, Immutep is positioned to be at the forefront of immunotherapy innovation.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Sydney, Australia",
    "founded": "2001",
    "website": "https://www.immutep.com",
    "ceo": "Marc Voigt",
    "social_media": {
        "twitter": "https://twitter.com/Immutep",
        "linkedin": "https://www.linkedin.com/company/immutep-limited/"
    },
    "investor_relations": "https://www.immutep.com/investors",
    "key_executives": [
        {
            "name": "Marc Voigt",
            "position": "CEO"
        },
        {
            "name": "Francois M. Barre-Sinoussi",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy Products",
            "products": [
                "Eftilagimod alpha (IMP321)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Immutep Limited | Innovative Immunotherapy Solutions",
        "meta_description": "Explore Immutep Limited, a leading biotechnology company dedicated to developing immunotherapy treatments for cancer and autoimmune diseases through innovative LAG-3 technologies.",
        "keywords": [
            "Immutep",
            "Immunotherapy",
            "LAG-3",
            "Cancer Treatment",
            "Biotechnology",
            "Eftilagimod alpha"
        ]
    },
    "faq": [
        {
            "question": "What is Immutep known for?",
            "answer": "Immutep is known for developing innovative immunotherapy treatments, particularly those targeting LAG-3 for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Immutep?",
            "answer": "Marc Voigt is the CEO of Immutep Limited."
        },
        {
            "question": "Where is Immutep headquartered?",
            "answer": "Immutep is headquartered in Sydney, Australia."
        },
        {
            "question": "What is Immutep's main product?",
            "answer": "Immutep's main product candidate is eftilagimod alpha (IMP321)."
        },
        {
            "question": "When was Immutep founded?",
            "answer": "Immutep was founded in 2001."
        }
    ],
    "competitors": [
        "BMY",
        "REGN",
        "MRNA",
        "NVS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "PFE",
        "JNJ"
    ]
}